SCHEDULE 13G/A: Wellington Management Group Discloses 5.0% Stake in Myriad Genetics

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a 5.0% beneficial ownership stake in Myriad Genetics, Inc. as of March 31, 2025.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP have filed an Amendment No. 4 to Schedule 13G.
• The filing reports beneficial ownership of Common Stock in Myriad Genetics, Inc. (CUSIP: 62855J104).
• As of March 31, 2025, the aggregate amount beneficially owned by each reporting person is 4,592,264 shares.
• This represents 5.0% of the class of Myriad Genetics, Inc. Common Stock.
• The reporting persons have shared voting power over 3,828,136 shares and shared dispositive power over 4,592,264 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: Neutral. This is a routine regulatory filing disclosing an ownership stake, not providing performance or strategic updates that would influence sentiment.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in Myriad Genetics, a company operating in the genetic testing and precision medicine industry. Large institutional holdings like this can signal investor confidence, though this specific filing is a routine disclosure of a passive stake.

Stakeholder Impact

• This filing primarily impacts shareholders by providing transparency on significant institutional ownership. It indicates that a major investment firm holds a substantial, albeit passive, stake in Myriad Genetics, which could be viewed positively by other investors as a sign of institutional confidence.

Key Dates

Keywords

Myriad Genetics Inc., Wellington Management Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, MRMD